Citation Impact
Citing Papers
Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro
2019
Rheumatoid arthritis
2018 Standout
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
Ruxolitinib: A Review in Polycythaemia Vera
2015
Ciprofloxacin
1988
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
2011
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
2017
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
The promise of Janus kinase inhibitors in the treatment of hematological malignancies
2016
Down syndrome
2020 Standout
Biological Therapies for Atopic Dermatitis: A Systematic Review
2021
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
2015
Trisomy 21 consistently activates the interferon response
2016
Three Decades of β-Lactamase Inhibitors
2010 Standout
Dosing Adjustment of 10 Antimicrobials for Patients with Renal Impairment
1995
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
2020
Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study
2019
Microbiological and Clinical Aspects of Infection Associated with Stenotrophomonas maltophilia
1998 Standout
Factors Related to Errors in Medication Prescribing
1997 Standout
Baricitinib for the treatment of rheumatoid arthritis
2016
Works of Thomas Emm being referenced
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
2014
The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
2011
Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans
2010
The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers
2011
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function
1987